Micronised Resveratrol as a Treatment for Friedreich Ataxia
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy of micronised resveratrol as a treatment for
FRDA, in terms of reducing the severity of ataxia symptoms at 24 weeks, through a randomised
blinded, placebo controlled crossover trial.